BioCentury | Jan 12, 2009
Company News
Boston Scientific, Labcoat Ltd. deal
...sum. Boston Scientific gains Labcoat's Jactax Stent, which combines Boston Scientific's Liberte paclitaxel-eluting stent with Labcoat's...
...to treat coronary artery disease (CAD) in 1H09. Boston Scientific said it will evaluate the Labcoat...
...use in its paclitaxel and everolimus drug-eluting stent programs. Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Labcoat Ltd....
...to treat coronary artery disease (CAD) in 1H09. Boston Scientific said it will evaluate the Labcoat...
...use in its paclitaxel and everolimus drug-eluting stent programs. Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Labcoat Ltd....